Tag: Neuroprotection

In March 2025, the U.S. Food and Drug Administration (FDA) approved Tenecteplase (TNKase) for acute ischemic stroke, marking the first new thrombolytic drug approval for this condition in nearly 30 years. This significant development directly addresses the key question: **What is the new drug for stroke patients?** It offers a faster, more streamlined approach to dissolving blood clots and is already changing clinical practice.

A medically induced coma is a critical intervention used to protect the brain from swelling and further injury, often by reducing its metabolic rate by up to 60%. But what is a short term medically induced coma in practice and why is it used?

Losartan, a common blood pressure medication, has demonstrated promising anti-inflammatory and neuroprotective properties in various preclinical studies. This has led researchers to investigate a crucial question: **Does losartan help with brain inflammation?** Recent evidence points to several mechanisms by which losartan may exert beneficial effects on the brain's inflammatory processes.

Originally recognized for its cardioprotective effects in treating angina, trimetazidine is a metabolic agent that also exerts significant effects within the central nervous system. By shifting cellular energy metabolism and inhibiting oxidative damage, trimetazidine affects the brain through a multi-faceted mechanism, with both therapeutic potential and notable side effects.

While fenofibrate is primarily known as a lipid-lowering medication for hypercholesterolemia and hypertriglyceridemia, preclinical research suggests that it also exerts several pharmacological effects on the central nervous system (CNS). These intriguing effects stem from its primary mechanism of action: activating the nuclear receptor peroxisome proliferator-activated receptor alpha ($$PPAR-\alpha$$).

Epidemiological studies have shown a consistent inverse correlation between smoking and the incidence of Parkinson's disease, suggesting there may be neurological benefits of nicotine. This intriguing finding has driven modern research into its therapeutic potential for various cognitive and neurodegenerative conditions, independent of tobacco use.

Piracetam was the first nootropic drug created to modulate cognitive function without causing sedation. Understanding **how to give piracetam IV** is a critical topic reserved for healthcare professionals, involving strict protocols for safety and efficacy in clinical settings like acute stroke treatment.

Approved by the FDA in 1995, riluzole was the first drug available for treating amyotrophic lateral sclerosis (ALS) and is one of the only medications shown to slow the disease's progression [1.8.4, 1.8.5]. So, **what is the pharmacology and mechanism of action of riluzole** that grants it this neuroprotective effect?

A 2020 study using a mouse model with genetically enhanced inflammation showed that ibuprofen treatment reduced neuroinflammation and resulted in significant improvements in cognitive function. This suggests potential, but also complexity, when exploring how and if **will ibuprofen reduce brain inflammation** in humans.

Ivermectin is an antiparasitic medication that works by targeting the nervous system of invertebrates. However, the human nervous system is largely protected from ivermectin's effects at standard therapeutic doses due to the blood-brain barrier. Research into whether **ivermectin can help the nervous system** in humans must carefully weigh promising preclinical findings against significant risks of neurotoxicity under specific conditions.